Reading AGPU? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track AGPU free→Reading AGPU? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track AGPU free→QuarterlyIQ Insights · AGPU
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On May 15, 2026, Axe Compute Inc. (the “Company”) issued a press release announcing its financial results for the quarterly period ended March 31, 2025. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information set forth in this Current Report on Form 8-K (including Exhibit 99.1) is deemed to be “furnished” and shall not be deemed to be…
Other Events. On May 15, 2026, Axe Compute Inc., a Delaware corporation, (the “Company”), filed a prospectus supplement (the “Prospectus Supplement) to the prospectus, dated May 21, 2024, filed with the Securities and Exchange Commission as part of its registration statement on Form S-3 (333-279123) (the “Registration Statement”), as supplemented by its prospectus supplement, dated May 21, 2024, as further supplemented by the prospectus supplements dated April 18, 2025 and October 29, 2025, a…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of Chief Financial Officer On April 10, 2026, Josh Blacher advised Axe Compute Inc. (the "Company") of his intention to resign from his position as Chief Financial Officer of the Company, effective May 18, 2026. Mr. Blacher’s resignation was not due to any disagreement with the Company on any matter relating to the Company’s operations,…
Other Events. On April 1, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding expected income trajectory, business model performance, and market opportunity. These statements involve known and unknown risks and uncertaintie…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of President of the Company On April 1, 2026, the Board of Directors of Axe Compute Inc. (the "Company") appointed Kyle Okamoto, age 42, to serve as President of the Company, effective April 1, 2026. Mr. Okamoto most recently served as Chief Technology Officer of Aethir, a distributed GPU cloud infrastructure and AI compute platform com…
Results of Operations and Financial Condition. On March 31, 2026, Axe Compute Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2025. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information set forth in this Current Report on Form 8-K (including Exhibit 99.1) is deemed to be “furnished” and shall not be deemed to be “filed”…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Dr. Theodore Zhu and Thorston Dirks to the Board of Directors On March 3, 2026, Axe Compute Inc. (the “Company”) announced that its board of directors (the “Board”) has appointed Dr. Theodore Zhu and Mr. Thorston Dirks as members of the Board. Dr. Zhu, has served as the Founder and Chairman of Iotelligent Technology since 2011, where…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Termination of Chief Executive Officer and Resignation from the Board On February 6, 2026, the board of directors (the “Board”) of Axe Compute Inc. (the “Company”) voted to terminate, without cause, the employment of Raymond F. Vennare with the Company, effective as of February 9, 2026. In connection with his termination, Mr. Vennare entered into a…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 15, 2026 (i) Shawn Matthews resigned as a director of Axe Compute Inc. (the “Company”), effective as of January 15, 2026, and (ii) Veena Rao resigned as a director of the Company, effective as of January 30, 2026. The resignation of each of Mr. Matthews and Ms. Rao is not based on any disagreement with the Company on any matter relating…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 10, 2025, Axe Compute Inc. (f/k/a Predictive Oncology Inc.) (the “Company”) entered into an amendment (the “Amendment”) to the employment agreement (the “Employment Agreement”) with Raymond F. Vennare, Chief Executive Officer of the Company, dated as of November 1, 2022. The Amendment provides that, effective retroactively to November 1…
Departure of Directors or Principal Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Predictive Oncology Inc. (the “Company”) held its 2025 annual meeting of stockholders on November 25, 2025 (the “Annual Meeting”). At the Annual Meeting, the stockholders of the Company approved an amendment (the “Amendment”) to the Company’s 2024 Equity Inventive Plan (the “2024 Plan”) to, among other things, increase the shares available for is…
Results of Operations and Financial Condition. On November 14, 2025, Predictive Oncology Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2025 and provided an update on its digital asset strategy. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information set forth in this Current Report on Form 8-K (including Exhibit 99.…
Other Events. On October 29, 2025, Predictive Oncology Inc., a Delaware corporation, (the “Company”), filed a prospectus supplement (the “Prospectus Supplement) to the prospectus, dated May 21, 2024, filed with the Securities and Exchange Commission as part of its registration statement on Form S-3 (333-279123) (the “Registration Statement”), as supplemented by its prospectus supplement, dated May 21, 2024, as further supplemented by the prospectus supplements dated April 18, 2025 and June 2,…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Nancy Chung-Welch Resignation On September 25, 2025, Nancy Chung-Welch, Ph.D. resigned from the Board of Directors (the “ Board ”), effective as of the Closing Date and subject to the successful closing of the Private Placements. Ms. Chung-Welch’s resignation was not the result of any dispute or disagreement with the Company or the Company’s Board…
Unregistered Sales of Equity Securities. The information contained in
Other Information. Upon the anticipated closing of the Private Placements on or about October 2, 2025 and the transactions contemplated thereby, the predominant business activity of the Company will be the Company’s digital asset treasury strategy, which is focused on the ATH token. Aethir is a leading decentralized physical infrastructure network developed by DCI that provides a decentralized graphics processing unit (“ GPU ”) network, which connects producers and consumers of GPU compute po…
Entry Into a Material Definitive Agreement. Private Placement (Cash Offering) Cash Securities Purchase Agreement On September 29, 2025, Predictive Oncology Inc., a Delaware corporation (the “ Company ”), entered into a securities purchase agreement (the “ Cash Securities Purchase Agreement ”) with certain accredited investors (the “ Cash Purchasers ”) pursuant to which the Company agreed to sell and issue to the Cash Purchasers in a private placement (the “ Cash Offering ”) an aggregate of (i…
Material Modification to Rights of Security Holders The information set forth under
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 9, 2025, the Board of Directors (the “Board”) of Predictive Oncology Inc. (the “Company”), upon the recommendation of the Compensation Committee of the Board, determined that it was appropriate to award restricted stock units (“RSUs”) as a form of compensation for employees, consultants and directors, to be granted under the Company’s…
Entry into a Material Agreement. On August 26, 2025, Predictive Oncology Inc., a Delaware corporation (“ Predictive Oncology ” or the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with an accredited investor (the “ Investor ”) for the sale by the Company of 543,544 shares (the “ Shares ”) of the Company’s common stock, par value $0.01 per share (the “ Common Stock ”) at a purchase price of $0.76 per Share in a private placement. The offering closed on…
In the Purchase Agreement, the Investor represented to the Company, among other things, that it is an “accredited investor” (as such term is defined in Rule 501(a)(3) of Regulation D under the Securities Act of 1933, as amended (the “Securities Act”)). The issuance of the Shares pursuant to the Purchase Agreement has been issued and sold by the Company to the Investor in reliance upon the exemptions from the registration requirements of the Securities Act afforded by Section 4(a)(2) of the Se…
Results of Operations and Financial Condition. On August 14, 2025, Predictive Oncology Inc. issued a press release attached hereto as Exhibit 99.1 announcing its financial results for the quarter ended June 30, 2025.
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On July 8, 2025, the Company received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the bid price for the Company’s common stock had closed below $1.00 per share for 30 consecutive business days, and that the Company is therefore not in compliance with the minimum bid price requirement for continued listing on The Na…
In the SEPA, the Investor represented to the Company, among other things, that it is an “accredited investor” (as such term is defined in Rule 501(a)(3) of Regulation D under the Securities Act of 1933, as amended (the “Securities Act”)). The issuances of shares of Common Stock pursuant to the SEPA have been or will be issued and sold by the Company to the Investor in reliance upon the exemptions from the registration requirements of the Securities Act afforded by Section 4(a)(2) of the Secur…
Entry into a Material Agreement. On July 1, 2025, Predictive Oncology Inc., a Delaware corporation (“ Predictive Oncology ” or the “ Company ”) entered into a Standby Equity Purchase Agreement (“ SEPA ”) with YA II PN, LTD., a Cayman Islands exempt limited company (the “ Investor ”) pursuant to which the Company has the right to sell to the Investor up to $10 million (the “ Commitment Amount ”) of shares of its common stock, par value $0.01 per share (the “ Common Stock ”). Upon the satisfact…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.